Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

American Journal of Tropical Medicine and Hygiene

Volumn 54, Issue 1, 1996, Pages 62-66

  Looareesuwan, Sornchai ^a   Viravan, Chaisin ^a   Webster, H Kyle ^b   Kyle, Dennis E ^c   Hutchinson, David B ^d   Canfield, Craig J ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Becton Dickinson Co   (Singapore)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Pharmaceutical Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; DOXYCYCLINE; PROGUANIL; PYRIMETHAMINE; TETRACYCLINE;

ACUTE DISEASE; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; HUMAN; MALARIA FALCIPARUM; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; THAILAND;

EID: 0030023406     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.54.62     Document Type: Article

References (16)

1. Hudson AT, 1984. Lapinone, menoctone, hydroxynaphthoquinones and similar structures. Peters W, Richards, WHG, eds. Handbook of Experimental Pharmacology. Volume 68. Antimalarial Drugs. New York: Springer Verlag, 343-361.
2. Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DBA, Pudney M, Randall AW, Latter VS, 1991. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 17: 427-435.
3. Kovacs JA, 1992. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 340: 637-638.
4. Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock J, Falloon J, Feinberg J, Lavon S, Rogers M, Sattler F, 1993. Comparison of atovaquone (566C80) with trimethoprim-sulphamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 328: 1521-1527.
5. Bunnag D, Harinasuta T, 1987. The current status of drug resistance in Malaria. Int J Parasitol 17: 169-180.
6. Looareesuwan S, Harinasuta T, Chongsuphajaisiddhi T, 1992. Drug resistant malaria with special reference to Thailand. Southeast Asian J Trop Med Public Health 23: 621-634.
7. Pavanand K, Permpanich B, Chuanak N, Sookto P, 1974. Preservation of Plasmodium falciparum infected erythrocytes for in vitro cultures. J Parasitol 60: 537-539.
8. Webster HK, Boudreau EF, Pavanand K, Youngvanithchit K, Pang LW, 1985. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. Am J Trop Med Hyg 34: 228-235.
9. WHO, 1973. Advances in malaria chemotherapy. World Health Organ Tech Rep Ser 529: 30-32.
10. Berliner R, Butler T, 1946. Summary of the data on the drugs tested in man. Wiselogle FY, ed. A survey of antimalarial drugs 1941-1945. Volume I. Ann Arbor, MI: Edwards.
11. Fawaz G, Haddad FS, 1951. The effect of lapinone (M-2350) on P. vivax infections in man. Am J Trop Med 31: 569-571.
12. Canfield CJ, Rozman RS, 1974. Clinical testing of new antimalarial compounds. Bull World Health Organ 50: 203-212.
13. Gutteridge WE, 1993. Chemotherapy. Cox, FG, ed. Modern Parasitology. Second edition. Oxford: Blackwell Scientific Publications, 218-239.
14. Canfield CJ, Pudney M, Gutteridge WE, 1995. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 80: 373-381.
15. Pullman TN, Craige B, Alving AS, Whorton CM, Jones R, Eichelberger L, 1948. Comparison of chloroquine, quinacrine (atabrine), and quinine in the treatment of acute attacks of sporozoite-induced vivax malaria (Chesson strain). J Clin Invest 27: 46-50.
16. Coatney GR, Cooper WC, Young MD, 1950. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J Natl Mal Soc 9: 381-396.